RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Tocilizumab, a Novel Monoclonal Antibody Targeting IL-6 Signaling, Significantly Reduces Disease Activity in Patients with Rheumatoid Arthritis
JF MD Conference Express
YR 2007
FD SAGE Publications
VO 7
IS 4
SP 11
OP 11
DO 10.1177/155989770700700404
UL http://mdc.sagepub.com/content/7/4/11.1.abstract
AB The cytokine IL-6 plays a central role in maintaining chronic inflammation in rheumatoid arthritis (RA). Tocilizumab is the first humanized interleukin-6 receptor inhibiting monoclonal antibody and represents a novel mechanism of action to treat RA. This article presents data from the phase 3 Tocilizumab Pivotal Trial in Methotrexate Inadequate Responders [OPTION] international study, involving 623 patients with moderate to severe RA.